Richter Gedeon
RIG2.FRIG2.F · Stock Price
Historical price data
Overview
Richter Gedeon's mission is to improve patient lives through the research, development, and global commercialization of innovative pharmaceuticals. The company has achieved a dominant position in its core Central and Eastern European markets while expanding its international footprint, supported by a robust pipeline of 34 candidates. Its strategy is built on deep therapeutic expertise in women's health and CNS, vertical integration from API to finished product, and a disciplined approach to both organic R&D and strategic partnerships to fuel sustainable growth.
Technology Platform
A fully integrated pharmaceutical platform encompassing synthetic chemistry, API manufacturing, advanced drug delivery systems, and biotechnological capabilities for biosimilars, focused on Women's Health and CNS therapeutics.
Pipeline
34| Drug | Indication | Stage | Watch |
|---|---|---|---|
| spironolactone | Hypertension | Approved | |
| Myo-inositol + Clomiphene Citrate | Ovulation Induction | Approved | |
| Cariprazine | Bipolar I Disorder | Phase 3 | |
| Placebo + Cariprazine | Schizophrenia | Phase 3 | |
| RGB-14-P + Prolia® | Postmenopausal Osteoporosis | Phase 3 |
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Richter competes with global pharma giants (e.g., Bayer, Pfizer, J&J) in Women's Health and CNS, leveraging its vertical integration and deep regional expertise in CEE/CIS as key differentiators. Its strategy focuses on targeted leadership in core therapeutic areas rather than broad-scale competition.
